Th17 T cell-inducing vaccines for the prevention of ovarian cancer recurrence

$210,820P50FY2025CANIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications & trials

Paper 39606742 Paper 39574689 Paper 39562549 Paper 39495297 Paper 39470729 Paper 39464114 Paper 39149248 Paper 39030393 Paper 38837893 Paper 38775277 Paper 38733141 Paper 38723632 Paper 38659758 Paper 38636338 Paper 38627969 Paper 38621195 Paper 38585884 Paper 38496503 Paper 38496424 Paper 38480868 Paper 38443389 Paper 38364782 Paper 38300121 Paper 38191790 Paper 38147070 Paper 38091771 Paper 37986741 Paper 37967790 Paper 37918918 Paper 37910295 Paper 37823600 Paper 37734095 Paper 37550562 Paper 37541199 Paper 37493628 Paper 37380808 Paper 37372428 Paper 37371475 Paper 37369443 Paper 37339172 Paper 37333340 Paper 37267954 Paper 37220873 Paper 36960831 Paper 36948887 Paper 36823213 Paper 36790339 Paper 36709663 Paper 36688720 Paper 36647342 Paper 36639731 Paper 36572991 Paper 36517075 Paper 36401943 Paper 36379355 Paper 36323878 Paper 36210504 Paper 36193784 Paper 36103568 Paper 35972367 Paper 35911770 Paper 35400525 Paper 35370009 Paper 35301312 Paper 35260879 Paper 34945003 Paper 34885153 Paper 34876496 Paper 34810199 Paper 34789471 Paper 34782936 Paper 34697060 Paper 34654724 Paper 34632220 Paper 34600126 Paper 34385422 Paper 34367083 Paper 34356114 Paper 34321239 Paper 34317694 Paper 34224364 Paper 34162658 Paper 34158040 Paper 34107029 Paper 34082797 Paper 34049772 Paper 34045642 Paper 33925895 Paper 33850213 Paper 33842927 Paper 33832919 Paper 33545385 Paper 33507295 Paper 33420377 Paper 33407429 Paper 33390326 Paper 33342620 Paper 33175227 Paper 33057068 Paper 32929152

Abstract

The overall goal of this project is to perform preclinical and phase II clinical testing of a Th17-induced pulsed dendritic cell vaccine to assess its efficacy in preventing relapse of high grade ovarian cancer in first remission after debulking surgery and platinum-based adjuvant or neoadjuvant chemotherapy.

View original record on NIH RePORTER →